Inflammation is a common feature in most of the main neurodegenerative disorders, playing a pivotal role in the most prevalent Central Nervous System (CNS) diseases such as Alzheimer’s Disease, Parkinson’ Disease, Stroke, Amyotrophic Lateral Sclerosis or Multiple Sclerosis. Moreover, inflammation is also a key player in Peripheral Nervous System (PNS) disorders such as peripheral neuropathy or hearing loss, which can be caused by traumatic
injuries, infections, drug toxicity, or autoimmune diseases such as rheumatoid arthritis, diabetes or lupus among others. Most of the CNS and PNS disorders remain orphans in terms of a disease-modifying therapy currently available in clinics. Moreover, the majority of the available injectable or oral drugs can only slow down disease progress or ameliorate the symptoms.
As a result, the classical formulations cannot only have undesired side effects but also low delivery efficiency in the targeted site of action due to their inability to cross the blood-brain barrier (BBB) or the meninges. In this context, there is a critical need to develop new formulations that can improve drug delivery to the CNS and PNS in a pathological context, while reducing systemic side effects. Thus, to improve the efficient delivery of active molecules and minimize their side effects, nanocarriers, either organic or inorganic, with the ability to protect the drug, and cross more efficiently biological barriers have great potential as an alternative to traditional formulations. Additionally, exploring other administration approaches such as nose-to-brain represents a good option to avoid BBB while keeping the desired patient-friendly characteristic of the systemic administration. Other approaches such
as the intrathecal, or trans-tympanic administration can potentially overcome some of the limitations faced by the drug systemic administration.
This field has been blossoming for the last three decades, but there is still plenty of room to improve current treatments against CNS and PNS disorders from a biomaterial-based approach. Thus, we welcome innovative and original articles, comprehensive reviews, and short communications related to biomaterials and drug delivery systems aiming to tackle inflammation associated with CNS and PNS disorders.
The scope of this Research Topic includes, but is not limited to the following biomaterial and drug delivery-focused themes:
- Neuroinflammation
- Neurodegeneration
- CNS disorders (such as Multiple Sclerosis, Stroke, and Parkinson and Alzheimer’s disease)
- Brain cancers
- Hearing loss
- Peripheral neuropathy and pain management
- Biomaterial-based tools for CNS/PNS diagnosis
Keywords:Central Nervous System, Peripheral Nervous System, Neurodegeneration, CNS disorders, Blood Brain Barrier, Neuropathy, Hearing Loss, Pain, Inflamation, Brain Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Inflammation is a common feature in most of the main neurodegenerative disorders, playing a pivotal role in the most prevalent Central Nervous System (CNS) diseases such as Alzheimer’s Disease, Parkinson’ Disease, Stroke, Amyotrophic Lateral Sclerosis or Multiple Sclerosis. Moreover, inflammation is also a key player in Peripheral Nervous System (PNS) disorders such as peripheral neuropathy or hearing loss, which can be caused by traumatic
injuries, infections, drug toxicity, or autoimmune diseases such as rheumatoid arthritis, diabetes or lupus among others. Most of the CNS and PNS disorders remain orphans in terms of a disease-modifying therapy currently available in clinics. Moreover, the majority of the available injectable or oral drugs can only slow down disease progress or ameliorate the symptoms.
As a result, the classical formulations cannot only have undesired side effects but also low delivery efficiency in the targeted site of action due to their inability to cross the blood-brain barrier (BBB) or the meninges. In this context, there is a critical need to develop new formulations that can improve drug delivery to the CNS and PNS in a pathological context, while reducing systemic side effects. Thus, to improve the efficient delivery of active molecules and minimize their side effects, nanocarriers, either organic or inorganic, with the ability to protect the drug, and cross more efficiently biological barriers have great potential as an alternative to traditional formulations. Additionally, exploring other administration approaches such as nose-to-brain represents a good option to avoid BBB while keeping the desired patient-friendly characteristic of the systemic administration. Other approaches such
as the intrathecal, or trans-tympanic administration can potentially overcome some of the limitations faced by the drug systemic administration.
This field has been blossoming for the last three decades, but there is still plenty of room to improve current treatments against CNS and PNS disorders from a biomaterial-based approach. Thus, we welcome innovative and original articles, comprehensive reviews, and short communications related to biomaterials and drug delivery systems aiming to tackle inflammation associated with CNS and PNS disorders.
The scope of this Research Topic includes, but is not limited to the following biomaterial and drug delivery-focused themes:
- Neuroinflammation
- Neurodegeneration
- CNS disorders (such as Multiple Sclerosis, Stroke, and Parkinson and Alzheimer’s disease)
- Brain cancers
- Hearing loss
- Peripheral neuropathy and pain management
- Biomaterial-based tools for CNS/PNS diagnosis
Keywords:Central Nervous System, Peripheral Nervous System, Neurodegeneration, CNS disorders, Blood Brain Barrier, Neuropathy, Hearing Loss, Pain, Inflamation, Brain Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
